Centessa Pharmaceuticals Finalizes Separation and Advisory Agreement with Former CEO

summarizeSummary

Centessa Pharmaceuticals plc entered into an Advisory Agreement and Separation Agreement with former CEO Dr. Saurabh Saha, detailing his advisory role, equity vesting, and bonus payments following his departure.

check_boxKey Events

• Advisory Agreement Established

  Former CEO Dr. Saurabh Saha will provide advisory services to the company for an initial six-month period at an hourly fee of $376.00, plus business expense reimbursement.

• Separation Agreement Details

  The agreement includes vesting of equity grants due on or prior to February 2, 2026, forfeiture of equity due to vest after that date, and a bonus payment equal to 100% of his target bonus for 2025, subject to Compensation Committee approval.

• General Release of Claims

  The Separation Agreement incorporates a general release of claims, which becomes effective after a seven-business-day revocation period, providing legal protection for the company.

auto_awesomeAnalysis

Centessa Pharmaceuticals plc has formalized the separation terms for its former Chief Executive Officer, Dr. Saurabh Saha, who stepped down on January 1, 2026. This filing provides crucial details regarding his transition to an advisory role and the financial arrangements of his departure. The Advisory Agreement ensures Dr. Saha will continue to provide services for an initial six-month period, offering continuity during the leadership transition. The Separation Agreement outlines the vesting of specific equity grants, forfeiture of future vesting, and a bonus payment for 2025, which are important for understanding the company's compensation obligations related to the executive change. The inclusion of a general release of claims is a standard protective measure for the company.